The pathophysiological mechanism of kidney injury caused by *Beni-koji Choleste-*

***Help*/puberulic acid is proximal tubular mitochondrial dysfunction**

Yuta Sekiguchi[1], Makiko Mori[1], Haruka Maruyama[1,2], Yuki Nakao[1], Hiroaki Kikuchi[1], Shintaro

Mandai[1], Fumiaki Ando[1], Koichiro Susa[1], Takayasu Mori[1], Yuma Waseda[3], Soichiro Yoshida[3],

Yasuhisa Fujii[3], Wakana Shoda[4], Daiei Takahashi[4], Eisei Sohara[1], Shinichi Uchida[1], Yutaro Mori[1]

[1]Department of Nephrology and [3]Department of Urology, Graduate School of Medical and Dental

Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan.

[2]Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533,

Japan

[4]Department of Nephrology, Japanese Red Cross Musashino Hospital, Tokyo 180-0023, Japan.

Lead contact and Corresponding author:

Yutaro Mori, MD, PhD

Department of Nephrology

Graduate School of Medical and Dental Sciences

Institute of Science Tokyo

1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan

Phone: +81-3-5803-5214; Fax: +81-3-5803-5215; Email: y-mori.kid@tmd.ac.jp

Abstract

In March 2024, kidney injury sometimes accompanied with Fanconi syndrome caused by a supplement made from red yeast rice (*Beni-koji Choleste-Help*) were reported in Japan. By November 24, 2024, 2,628 people had visited medical facilities, resulting in a social problem. Many patients still have a decline in eGFR. The previous report, however, did not indicate anything other than that puberulic acid which newly identified nephrotoxicity was contained in toxic lots. The pathophysiology of those nephropathies should be determined. Here, we discovered that mitochondrial dysfunction in renal proximal tubular epithelial cells plays a pivotal role in them. A patient renal biopsy sample showed Kidney Injury Molecule-1 (KIM-1) expression in proximal tubules surrounded by activated myofibroblasts, indicating acute tubular damage and interstitial fibrosis associated with injured tubules. Mice treated with the toxic lot of *Choleste-Help* and puberulic acid showed kidney injury with Fanconi syndrome-like urinary findings. Pathological sections showed tubular necrosis and interstitial fibrosis. RNA-seq on whole kidneys of those mice presented the renal damage caused by *Choleste-Help* and puberulic acid produced similar RNA patterns, indicating puberulic acid is a causative agent. Gene Ontology (GO) analysis comparing the normal and toxic lot revealed downregulation of mitochondrial-related pathways. Puberulic acid also showed toxicity on human primary epithelial cells and tubular organoids. *In vitro* experiments with human primary cells revealed that it causes mitochondrial damage at first and leads to cell death, mainly necrosis. Thus, puberulic and a toxic lot of *Choleste-Help* cause direct mitochondrial damage on tubular epithelial cells, followed by necrosis.

Keywords

Acute kidney injury, organoid, tubuloid, puberulic acid, Fanconi syndrome

43 **Graphical Abstract**

The pathophysiological mechanism of kidney injury caused by Beni-koji Choleste-Help/puberulic acid is proximal tubular mitochondrial dysfunction

Methods

Puberulic acid or Choleste-Help

Dose

Human Cell Model

Tubuloid   Primary cultured cell

Biological model

Yuta Sekiguchi, ei al. 2025

Findings

RPTECs

Transporter

Endocytosis

Puberulic acid

ATP↓

Mitochondrial Damage

ROS↑

Necrosis → DAMP S

Inflammation

Fibrosis

CONCLUSION:Both of Choleste-Help and Puberulic acid nephropathy cause mitochondrial damage on tubular epithelial cells and relatively little apoptosis

47 **Translational Statement**

48 Our research revealed the pathophysiology of puberilic acid nephropathy, which suffers many

49 patients. And we used not only animal models, but human kidney-derived primary cultured tubular

50 epithelial cells and its 3D organoids, which are ones of the closest models of human body.

Introduction

In recent years, due to growing health consciousness, supplements and herbal medicines are widely used. However, these often produce side effects.[1,2] From the second half of 2023 to 2024, a serious health issue arose in Japan. Multiple cases of kidney dysfunction associated with Benikoji tablets were reported, prompting Kobayashi Pharmaceutical Co., Ltd. to implement a voluntary recall on March 22, 2024.[3] The supplement most taken by patients was *Beni-koji Choleste-Help*（*Choleste-Help*）. This supplement, which contains Monascus-derived red yeast[4] and a compound structurally similar to the cholesterol-lowering drug lovastatin, was marketed as achieving similar effects at lower concentrations.[5] Patients who took these supplements developed acute kidney injury, proteinuria, and Fanconi syndrome[6-8], and many patients still had CKD-level kidney damage 120 days after starting treatment.[9] A compound called puberulic acid and two other new compounds were identified as causative substances, and puberulic acid is the most likely causative substance[10,11], but only little information[12,13] are available at this time. Puberulic acid was originally developed as an antimalarial agent; however, its development was discontinued due to lethality observed in mice at high doses, the cause of which remains unknown.[14] Aristolochic acid, the most widely known kidney-toxic substance derived from traditional Chinese medicine, is known not only to cause tubular damage, but also to induce CKD and increase the incidence of cancer[15-17]. Therefore, it is necessary to collect various information on this substance, including its damaged pathways and clinical course. We have succeeded in identifying the main pathways of damage to the kidneys caused by this substance from a basic medical perspective, and we describe this in this paper. To the best of our knowledge, this is the first study to demonstrate the toxicity of puberulic acid in human cells.

Methods

Immunostaining of human renal biopsy samples

Written informed consent was obtained by the patient of *Choleste-Help* nephropathy for publishing

reports regarding renal biopsy and other clinical information. After deparaffinization with xylene,

antigen retrieval was performed by heat-induced epitope retrieval using boiling in Antigen

Unmasking Solution (Citric Acid base, H-3300, Vector Laboratories Inc.). Sections were

incubated with a goat anti-KIM-1 antibody (1:200, AF1750, R&D Systems, MN, USA) and a

rabbit anti-α-smooth muscle actin (α-SMA) antibody conjugated with Cy3 (1:400, C6198, Sigma-

Aldrich). For the detection of KIM-1, an Alexa Fluor 488-conjugated donkey anti-goat IgG

secondary antibody (1:500, A11055 Thermo Fisher Scientific) was used.

Animal treatment and tissue collection

Eight-week-old male C57BL/6J mice were used for all experiments. Mice were randomly assigned

to four groups (n = 6-10 per group): (1) control (PBS), (2) *Choleste-Help* normal batch (1,000

mg/day), (3) *Choleste-Help* toxic batch (1,000 mg/day), and (4) puberulic acid (1 mg/day).

Treatments were administered either by oral gavage or intraperitoneal injection for six consecutive

days, followed by a one-day rest period. On day 7, mice were euthanized, and bloods, urines, and

whole kidneys were rapidly harvested, snap-frozen in liquid nitrogen, and stored at −80°C until

RNA extraction. Hematological and urinary analyses were outsourced and performed by Oriental

Yeast Co., Ltd.

Histological Preparation and Staining

Hematoxylin and eosin (H&E) staining was outsourced to the Research Core Center of Institute of

Science Tokyo. Masson's trichrome staining was performed using a standard protocol. For each

sample, one kidney sections were selected to reduce non-specific blue staining. Whole images of

the sections were acquired, and the fibrotic area, indicated by blue staining, was quantified using

Image J Fiji (https://imagej.net/software/fiji/downloads). The percentage of the blue-stained area

relative to the total kidney section area was calculated for each sample.

RNA-seq and analysis

Mouse whole kidney total RNA was extracted using Sepasol (Nacalai Tesque, Japan) and purified

with Direct-zol RNA Miniprep Plus Kit (Zymo Research, R2070). Samples (n = 5, each) with RIN

> 7.5 were processed by ReRexa Inc. using NEBNext kits and sequenced on NovaSeq X Plus (2

× 150 bp, ~ 40 million reads/sample). Reads were trimmed with fastp and quantified with Salmon

(GENCODE vM33). DEGs were identified using DESeq2 (padj < 0.05, |log2FC| > 1, baseMean >

10). PCA and heatmaps were generated in RStudio (Windows), with Salmon outputs from WSL2.

The details of experimental methods for RNA-seq analysis are described in **Supplementary**

Methods.

Cell culture experiment

Human kidney samples were collected from patients undergoing clinically indicated nephrectomy

at the Institute of Science Tokyo Hospital in Tokyo, Japan. The protocol was approved by the

Institutional Review Board of the Ethics Committee of Institute of Science Tokyo (M2022-005).

Primary human renal proximal tubular epithelial cells (hRPTECs) were isolated from unaffected

areas of kidneys removed during nephrectomy procedures performed on patients with renal cell

carcinoma or urinary tract malignancies by modifying a previously established protocol.[18,19]

Briefly, the isolation procedure involved mincing the human renal cortex and then digesting it in

a solution of Collagenase type II (1.0 mg/mL) (Worthington Biochemical, NJ, USA). The enzyme

reaction was terminated with fetal bovine serum (FBS), and the samples were resuspended in

hRPTECs culture medium containing DMEM/F-12 (Nacalai Tesque, Kyoto, Japan), with BSA

(Nacalai Tesque), Antibiotic–Antimycotic (ThermoFisher Scientific, MA, USA), hydrocortisone

(ThermoFisher Scientific, MA, USA), ITS liquid media supplement (Sigma-Aldrich, MO, USA),

and human recombinant epidermal growth factor (EGF) (ThermoFisher Scientific, MA, USA).

Human renal tubuloids culture

hRPTECs were seeded onto ultralow attachment plates at a density of 5.0×10^5 cells/well using

Advanced RPMI 1640 medium (ThermoFisher Scientific), supplemented with 5% FBS. After a 2–

3-day incubation period, Matrigel (Corning, NY, USA) was added to stimulate tubuloid formation.

The following day, the culture medium was changed to Advanced RPMI 1640 medium with 5%

FBS, EGF, FGF2, and HGF (tubuloids media). Media was changed three times in a week to

maintain optimal cell growth conditions. Tubuloids were usually ready for experimentation within

1–2 weeks of starting the culture.

Western blot analysis

The samples were lysed, and the protein was purified by using a lysis buffer [50 mM Tris-HCl (pH

7.5), 150 mM NaCl, 1% Nonidet P-40, 1 mM sodium orthovanadate, 50 mM sodium fluoride, and

protease inhibitor cocktail]. Since the protein content of the Tuburoids was low, four wells under

the same conditions were combined into a single sample. Proteins were separated by 10% SDS-

PAGE and transferred onto a nitrocellulose membrane. Protein bands were visualized using

Western Blue (Promega, WI, USA). Rabbit anti–ERK1/2 (p44/42 MAPK) antibody (9102S, Cell

Signaling Technology) (1:1000) or rabbit anti-beta actin antibody (4967S, Cell Signaling

Technology) (1:1000) was used as a loading control. Primary antibodies were also used, such as

rabbit anti-KIM-1 polyclonal antibody (PA5-79345, Thermo Fisher Scientific) (1:1000), rabbit

anti Phospho-Histone H2AX (Ser139) antibody (9718S, Cell Signaling Technology) (1:1000). As

secondary antibody, anti-rabbit IgG alkaline phosphatase–conjugated secondary antibody (S373B,

Promega) was used. Densitometry was performed by using Image J Fiji.

Cell viability assay

Primary cultured cells were seeded at a density of 2×10^4 cells per well in 96-well plates. After

reaching confluence in two days post-passaging, cells were treated with the indicated compound

for 48 hours. Cell viability was assessed using Cell Count Reagent SF (Nacalai Tesque, #07553)

according to the manufacturer's instructions. Cells were incubated with the reagent (10% v/v) at

37 °C for 1 hour. Absorbance was measured at 450 nm using a microplate reader (FilterMax F5,

Molecular Devices). Cell viability was expressed as a percentage of absorbance relative to vehicle

control. The EC_{50} value was estimated using a four-parameter logistic model fitted to the viability

data. Due to data sparsity at higher concentrations, the confidence intervals could not be fully

resolved. Therefore, the EC_{50} value should be interpreted with caution.

Annexin V assay and flow cytometry

Primary cultured cells were seeded at a density of 5×10^5 cells per well in 12-well plates. After

reaching confluence in two days post-passaging, cells were treated with the indicated compound

for 48 hours. Following treatment, 1×10^5 cells were collected and stained using the Annexin V

Apoptosis Detection Kit (Nacalai Tesque, product number 15342-54) according to the

manufacturer's instructions. Flow cytometric analysis was performed using a FACS Lyric™

system (BD Biosciences). Data was analyzed with FlowJo software (BD Biosciences), and cell

populations were classified into live, early apoptotic, and late apoptotic/necrotic based on Annexin

V and propidium iodide (PI) staining patterns.

JC-1 staining

Primary cultured cells were seeded at a density of 5×10^5 cells per well in 12-well plates. In three

days post-passaging, cells were treated with the indicated compound for 18 or 24 hours. Then,

mitochondrial membrane potential was assessed using the JC-1 dye (T3168, Thermo Fisher

Scientific) according to the manufacturer's instructions. Briefly, cells were incubated with 1.5 μM

JC-1 in culture medium at 37 °C for 20 minutes. After incubation, cells were washed twice with

PBS and analyzed by confocal microscopy (Eclipse Ti2 from Nikon, excitation/emission:

488/530 nm for green monomers, 540/590 nm for red aggregates), with the NIS-Elements

Advanced Research microscope system serving as the operating system. Fluorescence images

were analyzed using ImageJ Fiji. For each well, three fields of view were randomly selected, and

the entire field area was defined as the region of interest (ROI). The red-to-green fluorescence ratio

was calculated to assess mitochondrial membrane potential.

ATP measurement

Primary cultured cells were seeded at a density of 2×10^4 cells per well in 96-well plates. After

reaching confluence in two days post-passaging, cells were treated with the indicated compound

for 6, 24 or 48 hours. Cellular ATP levels were quantified using the CellTiter-Glo® 2.0 Cell

Viability Assay (Promega, Madison, WI, USA) according to the manufacturer's instructions.

Luminescence was measured using a Varioskan™ LUX Multimode Microplate Reader (Thermo

Fisher Scientific, Waltham, MA, USA). The luminescence intensity, which is proportional to the

amount of ATP, was recorded and normalized to control samples.

Quantification and statistical analyses

Figure Legends indicate the number of samples assayed in each experiment. One-way ANOVA

was used for general comparisons. When data were normalized to the control group mean, Welch's

ANOVA was applied. When each value was individually normalized to its corresponding control,

the Kruskal–Wallis test was used. A p-value < 0.05 was considered statistically significant.

Statistical significance was indicated by asterisks as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$,

**** $p < 0.0001$. All statistical analyses were performed with GraphPad Prism by GraphPad

Software Inc. (San Diego, CA, USA).

Study approval

The protocol for human kidney samples for primary culture and the one for analyzing human

kidney biopsy samples were approved by the Institutional Review Board of the Ethics Committee

of Institute of Science Tokyo (M2022-005, I2024-097). Animal experiments were approved by the

Animal Care and Use Committee of Institute of Science Tokyo (A2023-109C3) according to the

animal experiment guidelines of the Japan Ministry of Education, Culture, Sports, Science and

Technology.

Results

A human kidney biopsy sample of a *Choleste-Help* patient show KIM-1 positive proximal

tubular epithelial cells surrounded by α-SMA positive cells

Renal biopsy samples obtained from a patient who visited our affiliated hospital revealed marked

tubular dilatation and detachment of tubular epithelial cells and tubular casts were observed in the

lumen of the renal tubules (**Figure 1a**), whose case we reported recently.[7] Immunostaining

demonstrated the presence of KIM-1–positive tubular epithelial cells, an established marker of

tubular injury,[20] along with surrounding expression of α-SMA, indicative of early fibrotic changes

associated with tubular epithelial damage (**Figure 1b**). Although the degree of renal injury in this

case was relatively mild, the findings suggest the presence of fibrosis at an early stage.

Wild type mice showed acute kidney failure and Fanconi-like phenotype by *Choleste-Help*

toxic lot and puberulic acid

To investigate the *in vivo* toxicity and underlying mechanisms, we administered *Choleste-Help*

(normal lot and toxic lot), the suspected causative compound puberulic acid, and vehicle (PBS) to

mice once daily for six days. Following a one-day drug holiday, the mice were sacrificed on day

7 (**Figure 2a, Supplementary Figure 1**).

In both the *Choleste-Help* toxic lot and puberulic acid groups, serum biochemical analysis

revealed elevated blood urea nitrogen (BUN) and creatinine (Cr) levels (**Figure 2b**). Urinalysis

showed increased urinary albumin-to-creatinine (Alb/Cr), glucose-to-creatinine (Glu/Cr), and N-

acetyl-β-D-glucosaminidase-to-creatinine (NAG/Cr) ratios, which is consistent not only with

tubular injury but also with Fanconi syndrome. These findings indicate that both compounds

induce proximal tubular injury, renal dysfunction, proteinuria, and a Fanconi syndrome-like

phenotype in mice, recapitulating features observed in human cases.

Histological examination using hematoxylin and eosin (HE) staining revealed tubular

dilatation and epithelial cell detachment (**Figure 2c**), consistent with human biopsy findings. In

addition, intratubular casts—also observed in human sample—were present in treated mice.

Furthermore, Masson's Trichrome staining demonstrated a significant increase in fibrotic areas in

both the *Choleste-Help* toxic lot and puberulic acid groups (**Figure 2d**). These results suggest that

Choleste-Help toxic lot and puberulic acid can induce renal fibrosis at an early stage *in vivo*.

Mice treated with *Choleste-Help* toxic lot and puberulic acid exhibited highly similar gene

expression profiles, as revealed by RNA-seq analysis

We performed bulk RNA sequencing (RNA-seq) using whole-kidney samples (n = 5 for each

sample) from the experimental groups as a transcriptomic analysis. Principal component analysis

(PCA) and hierarchical clustering (**Figure 3a, b**) demonstrated that the *Choleste-Help* toxic lot

and puberulic acid groups clustered closely together, indicating a high degree of similarity in their

transcriptomic responses.

To assess the overall transcriptomic changes and data quality, a volcano plot, generated to

compare gene expression between toxic lot vs normal lot and, and heatmap were generated (**Figure**

3c, d, Supplementary Figure 2). These visualizations illustrate the global expression landscape

and support the reliability and robustness of the dataset. In the Volcano plot, Spp1 and Havcr1

were among the top upregulated genes, supporting the validity of the model as a representation of

kidney injury.

Correlation analysis between differential gene expression profiles revealed a strong

correlation (Pearson's r = 0.736) between the comparisons of *Choleste-Help* toxic lot vs. normal

lot and puberulic acid vs. PBS (**Figure 3e**). Moreover, more than 70% of differentially expressed

genes (DEGs) overlapped between the two comparisons, suggesting that the toxic responses

induced by *Choleste-Help* toxic lot and puberulic acid are highly similar at the transcriptomic level

(**Figure 3f**).

Although the precise concentration of puberulic acid contained in *Choleste-Help* is

unknown and not equivalent to the dose used in the isolated puberulic acid group, the similarity in

gene expression patterns strongly suggests that puberulic acid is likely a major contributor to the

nephrotoxicity observed in *Choleste-Help* toxic lot.

Mitochondrial function was significantly suppressed indicated by comprehensive

transcriptomic analysis with RNA-seq

We performed Gene Ontology (GO) enrichment analysis based on the comparison between the

Choleste-Help toxic lot and the normal lot. Based on the GO cellular component (CC) analysis

using the absolute value of log2 fold change, the top 10 enriched terms included not only

membrane and cytoskeleton components but also mitochondria, indicating that mitochondrial

structures were among the most affected organelles (**Figure 4a**). Notably, all mitochondrial-related

terms showed a trend toward downregulation. Furthermore, in the GO biological process (BP)

analysis, the top 10 downregulated pathways were predominantly associated with mitochondrial

function (**Figure 4b**).

In addition, GO analysis of the "molecular function" category revealed downregulation of

various transporter activities, supporting the hypothesis that this compound induces a renal injury

pattern consistent with Fanconi syndrome (**Figure 4c**).

Puberulic acid exhibited approximately half the cytotoxicity of cisplatin in hRPTECs and

kidney injury marker KIM-1 and DNA damage marker γH2AX were upregulated following

puberulic acid exposure

To evaluate the potential nephrotoxicity of puberulic acid in humans, we exposed primary cultured

hRPTECs to puberulic acid for 48 hours and assessed cytotoxicity using a cell viability assay.

Cisplatin was included as a positive control under the same conditions. Puberulic acid exhibited

dose-dependent toxicity, with an EC_{50} of 61.78 μM, approximately twice that of cisplatin (EC_{50} =

32.27 μM), indicating moderate cytotoxicity relative to cisplatin (**Figure 5a**).

We further examined the effects of puberulic acid using both conventional 2D cultures and

3D-cultured renal tubuloids derived from hRPTECs. Puberulic acid was administered at 48-hour

intervals for a total of three exposures. Western blot analysis revealed increased expression of the

kidney injury marker KIM-1 in tubuloids and the DNA damage marker γH2AX in both models

following treatment (**Figure 5b, c**). Notably, the tubuloids responded to puberulic *acid* at

approximately one-tenth the concentration required in the 2D cultures, indicating higher sensitivity

in the 3D system.

DNA damage and its response are known to be associated with cellular senescence through

cell cycle arrest[21]. The senescence-associated secretory phenotype (SASP) is considered a driver

of chronic fibrosis progression.[22,23] In mouse RNA-seq data, Cdkn1a expression was markedly

upregulated, whereas Cdkn2a showed only a modest increase (**Supplementary Figure 3a**).

Furthermore, in the *in vitro* model with a 6-day exposure, no induction of p16 expression was

observed (**Supplementary Figure 3b**). These findings suggest that cell cycle arrest induced by

puberulic acid occurs without clear evidence of cellular senescence.

Annexin V assay revealed that necrosis accounted for most of the cell death

To evaluate the involvement of apoptosis, we performed live-cell immunostaining using Annexin

V and propidium iodide (PI), followed by flow cytometric analysis. As a positive control, cells

were treated with cisplatin, and the types of cell death were assessed at 48 hours post-treatment.

The results showed that, under conditions with comparable numbers of viable cells, the

proportion of apoptotic cells in the puberulic acid–treated group was approximately half that

observed in the cisplatin-treated group, indicating a relatively low level of apoptosis (**Figure 6a**).

Furthermore, at earlier points (24 and 40 hours), the proportion of apoptotic cells in the puberulic

acid group was even lower (**Figure 6b**).

These findings suggest that while puberulic acid does induce apoptosis, it occurs at

relatively low levels. This observation is consistent with the renal biopsy findings in human cases,

where necrosis was the predominant histological feature.

We also examined other forms of cell death, including necroptosis and pyroptosis

(**Supplementary Figure 4**); however, in our *in vitro* experiments, we did not observe upregulation

of pathway-specific molecules at the protein level, suggesting that necroptosis and pyroptosis are

not involved in puberulic acid-induced cell death.

In addition, at the 24-hour time point, exposure to 100 μM puberulic acid induced only

minimal cell death. Therefore, analyzing cells prior to this time point may provide further insights

into the upstream mechanisms responsible for puberulic acid–induced cytotoxicity.

324 **JC-1 staining and measuring of ATP revealed a decrease in mitochondrial membrane**

325 **potential and ATP depletion preceding the onset of cell death**

JC-1 staining was performed at 18- and 24-hours following treatment with 100 μM puberulic

acid—time points at which minimal cell death was observed (**Figure 7a**). At 18 hours, a reduction

in red fluorescence, indicative of healthy mitochondria, was already evident, accompanied by an

increase in green fluorescence, reflecting a loss of mitochondrial membrane potential. This trend

became more pronounced at 24 hours.

These findings indicate that mitochondrial dysfunction occurs prior to the onset of cell

death following puberulic acid exposure. Thus, puberulic acid–induced mitochondrial damage is

likely one of the primary causes of its cytotoxic effects.

In addition, ATP measurement using a luminescence-based assay revealed a reduction as

early as 6 hours after treatment (**Figure 7b**). This suggests that puberulic acid impairs ATP

production, likely through disruption of the mitochondrial respiratory chain.

Discussion

In this study, we have revealed potential pathophysiological mechanisms of puberulic acid or *Choleste-Help* toxic lot-induced nephropathy. As reported by Ministry of Health, Labour and Welfare in Japan, 1,961 people consulted with doctor and 348 people was hospitalized due to renal injury after taking *Choleste-Help*.[3] The social significance of this study is extremely great.

We observed acute renal fibrosis in mouse models treated with puberulic acid or *Choleste-Help* toxic lot as well as human patients. We also found out proximal tubular epithelial cell death after puberulic acid treatment[7,9] in a relatively short period, which was mainly necrosis. In the status of proximal tubular epithelial necrosis, Damage-Associated Molecular Patterns (DAMPs) are released from dead cell bodies, resulting in myofibroblast activation and/or immune cell infiltration.[24,25] This may explain the early onset of fibrosis observed in our model.

Mitochondrial damage was demonstrated by early reductions in ATP levels and JC-1 signals prior to cell death in hRPTECs, which was supported by RNA-seq data in mice treated with pubeluric acid or *Choleste-Help* toxic lot. In addition, a marked reduction in mitochondria in electron micrographs of kidneys from mice treated with puberulic acid was reported in a preprint,[12] which is consistent with our findings. Since apoptosis is an ATP-dependent process,[26,27] it is well known that necrosis tends to be predominant under conditions of ATP depletion.[28,29] Therefore, we speculate that the primary mitochondrial damage led to a relative deficiency in ATP, which in turn shifted the mode of cell death toward necrosis. Proximal tubular epithelial cells primarily generate ATP through mitochondrial oxidative phosphorylation, relying heavily on β-oxidation of fatty acids as an energy source, with minimal dependence on glycolysis. In the proximal tubule, a significant portion of solute reabsorption occurs via secondary active transport driven by the Na^+/K^+-ATPase, which requires a substantial amount of ATP.[30] When proximal tubular cells are

injured and mitochondrial dysfunction impairs energy production, ATP depletion ensues, resulting

in characteristic features of Fanconi syndrome may emerge, including glucosuria, aminoaciduria,

phosphaturia, bicarbonate loss leading to metabolic acidosis, and low molecular weight

proteinuria.[31] This is highly consistent with the Fanconi syndrome-like manifestations observed in

both humans and mice following treatment with puberulic acid and *Choleste-Help*. In the future,

we plan to investigate the detailed mechanisms of puberulic acid, including its uptake pathways

and long-term effects.

In summary, we are the first to demonstrate that puberulic acid and *Choleste-Help* exhibit

the same type of toxicity, which is predominantly necrosis. We also showed that mitochondrial

dysfunction precedes and likely contributes to this toxicity as one of its key mechanisms. We hope

that future studies building on this work will contribute to improving the prognosis and treatment

of patients suffering from such toxic effects.

Disclosure Statement

The authors declare that they have no conflicts of interest.

Data Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request. Requests for resources and reagents should be directed to the Lead Contact, Yutaro Mori (y-mori.kid@tmd.ac.jp).

Acknowledgment

We are deeply grateful to the generous study participants who agreed to donate segments of their resected kidneys for this research. This work was supported by Leading Initiative for Excellent Young Researchers (LEADER) from Ministry of Education, Culture, Sports, Science and Technology (to Y.M.), Grant-in-Aid for Research Activity Start-up (22K20881) and Grand-in-Aid for Scientific Research (B) (24K03249) from Japan Society for the Promotion of Science (to Y.M.), Innovation Idea Contest from Tokyo Medical and Dental University (TMDU) (in 2022 to Y.M. and in 2023 to Y.N.), Next Generation Researcher Training Unit from TMDU (to Y.M.) and Priority Research Areas Grant from TMDU (to Y.M.), Research Grant from Uehara Memorial Foundation (to Y.M.), Research Grant (Lifestyle-related diseases) from MSD Life Science Foundation (to Y.M.), Medical Research Grant from Takeda Science Foundation (to Y.M.), Academic Support from Bayer Yakuhin, Ltd. (to Y.M.), and Japan Agency for Medical Research and Development (AMED) (24gm6910017h0001) (to E.S.).

Author contributions

Figure Legends

Figure 1. A human kidney biopsy sample of a *Choleste-Help* nephropathy patient show renal tubular injury and necrosis and surrounded interstitial fibrosis.

(a) A HE staining on a human *Choleste-Help* nephropathy kidney. A scale bar: 200 μm.

(b) An immunostaining of KIM-1 and α-SMA on a *Choleste-Help* nephropathy kidney. Scale bars: 100 μm.

Figure 2. Wild type mice showed acute kidney failure and Fanconi-like phenotype by *Choleste-Help* toxic lot and puberulic acid.

(a) Schematic overview of animal experiments treated with *Choleste-Help* toxic lot or puberulic acid.

(b) Blood urea nitrogen (BUN), serum creatinine (Cr), urinary albumin (U-Alb), urinary glucose (U-Glu) and urinary N-acetyl-β-D-glucosaminidase (U-NAG) of mice treated with PBS control, *Choleste-Help* normal lot, toxic lot or puberulic acid (PA). n = 10 for control and for *Choleste-Help* normal lot, n = 9 for toxic lot and n = 6 for puberulic acid.

(c) HE stainings on mouse kidneys of PBS control (vehicle), *Choleste-Help* normal lot, toxic lot and pubeluric acid. Scale bars: 200 μm.

(d) Masson's Trichrome Stainings and statistical analysis of fibrotic areas on mouse kidneys PBS control (vehicle), *Choleste-Help* normal lot, toxic lot (n = 8, 2 samples without kidney damage excluded) and pubeluric acid. Scale bars: 200 μm.

Figure 3. Mice treated with *Choleste-Help* toxic lot and puberulic acid exhibited highly similar gene expression profiles, as revealed by RNA-seq analysis.

(a) Principal component analysis (PCA) of RNA-seq samples. PCA was performed using rlog-

transformed gene expression values. Each point represents one biological replicate. Samples

are color-coded by treatment group: control (orange), normal lot (green), toxic lot (blue), and

puberulic acid (magenta). PC1 and PC2 explain 86% and 4% of the total variance, respectively.

(b) Hierarchical clustering of RNA-seq samples. Samples were clustered based on Euclidean

distance calculated from rlog-transformed gene expression values. Clustering was performed

using complete linkage, and the resulting dendrogram illustrates the similarity of global

transcriptomic profiles across the four treatment groups: control, normal lot, toxic lot, and

puberulic acid. The x-axis labels represent individual biological replicates. Shorter branch

lengths indicate greater similarity in expression profiles.

(c) Heatmap of the top 30 differentially expressed genes (DEGs) across treatment conditions.

Row-scaled expression levels (Z-scores) of normalized RNA-seq counts are shown for the 30

most significant DEGs (padj < 0.05, |log2 fold change| > 1, baseMean > 10). Each row

represents a gene, and each column corresponds to a biological replicate. Samples are

annotated by treatment group: control (green), normal lot (blue), toxic lot (orange), and

puberulic acid (magenta). Both genes and samples were hierarchically clustered using

Euclidean distance and complete linkage. Color scale indicates standardized expression values

(Z-scores), with red representing higher expression and blue representing lower expression

relative to the mean of each gene.

(d) Volcano plot of differentially expressed genes between the toxic and normal lots. Each dot

represents a gene, with red and blue indicating significantly upregulated and downregulated

genes, respectively (adjusted p-value < 0.05 and |log2 fold change| > 1, baseMean > 10). Gray

points represent genes with no significant change. The top 10 upregulated and downregulated

genes were labeled based on adjusted p-value ranking. For improved visualization, genes with

extreme fold changes ($|\log2FC| > 10$, $n = 6$) were excluded from the plot. The total number of

significantly changed genes is indicated in the figure.

(e) Correlation of gene expression fold changes between treatment comparisons. Each point

represents a gene, with its log2 fold change (log2FC) in normal lot vs toxic lot (x-axis) and

puberulic acid vs control (y-axis). A Pearson correlation coefficient was 0.733. The red dashed

line represents a linear regression fit.

(f) Venn diagram showing the overlap of differentially expressed genes (DEGs) between

puberulic acid vs control and toxic lot vs normal lot. DEGs were defined by $padj < 0.05$,

$|\log2FC| > 1$, and baseMean > 10. A total of 4144 genes were shared between the two

comparisons, accounting for 63.8% of the union set.

Figure 4. Mitochondrial function was significantly suppressed indicated by comprehensive

transcriptomic analysis with RNA-seq

(a) GO Cellular Component (CC) enrichment analysis of differentially expressed genes. Dot plot

showing the top 10 enriched GO terms ($padj < 0.05$). The x-axis represents Gene Ratio (number

of input genes annotated in the term divided by the total number of input genes). The size of

each dot reflects the gene count per GO term, and the color scale indicates the adjusted p-value.

(b) GO-Biological Process enrichment of downregulated genes. Dot plot showing the top 10

significantly enriched GO terms ($padj < 0.05$) among genes that were downregulated (log2FC

< -1, baseMean > 10). The x-axis represents the Gene Ratio (the proportion of input genes

associated with each term). The color gradient reflects the adjusted p-value (Benjamini-

Hochberg correction), where red indicates higher significance. Bubble size corresponds to the

number of genes enriched in each term.

(c) GO-Molecular Function enrichment of downregulated genes. Dot plot showing the top 10

significantly enriched molecular function (MF) terms (padj < 0.05) among genes

downregulated (log2FC < -1, baseMean > 10). The x-axis represents the Gene Ratio, defined

as the proportion of input genes annotated to each GO term. Dot size indicates the gene count,

while dot color represents the adjusted p-value. Long GO term names were wrapped to improve

readability, and the figure height was adjusted to prevent axis label overlap.

Figure 5. Puberulic acid exhibited approximately half the cytotoxicity of cisplatin in

hRPTECs and a kidney injury marker and a DNA damage marker were upregulated

following puberulic acid exposure.

(a) Cell viability of hRPTECs treated with puberulic acid or cisplatin. n = 7 for each condition

(performed 9 assays and excluded highest and lowest values as outliner). EC_{50} was estimated

using a 4-parameter logistic model (see Methods). Due to data sparsity at higher concentrations,

this value should be interpreted with caution.

(b) Representative western blotting images of γH2AX and Erk1/2 as a loading control from lysate

of puberulic acid-treated hRPTECs. Graphs represent densitometric values of each band

normalized to the corresponding internal control.

(c) Representative western blotting images of γH2AX, KIM-1 and Erk1/2 as a loading control

from lysate of puberulic acid-treated human kidney-derived tuboloids. Graphs represent

densitometric values of each band normalized to the corresponding internal control.

Figure 6. Necrosis accounted for most of the cell death of hRPTECs treated with puberulic

acid.

(a) Representative plots of flow cytometry on hRPTECs treated with puberulic acid or cisplatin

stained with Annexin V and propidium iodide (PI) as Annexin V assay. The graph shows the

fold change in early apoptosis (Annexin V positive, PI negative) and late apoptosis/necrosis

(Annexin V positive, PI positive), normalized to the control group. Independent experiments

were conducted three times for both the cisplatin group (n = 3) and the puberulic acid group (n

= 5). Statistical analyses were performed on raw (non-normalized) data, and the results were

reflected in the corresponding graphs.

(b) Representative plots of flow cytometry on hRPTECs treated with 100 μM puberulic acid

measuring time course of cell death. The graph shows the fold change in early apoptosis

(Annexin V positive, PI negative) and late apoptosis/necrosis (Annexin V positive, PI positive),

normalized to the control group. Independent experiments were performed twice for both the

24-hour group (n = 3) and the 40-hour group (n = 2). Statistical analyses were performed on

raw (non-normalized) data, and the results were reflected in the corresponding graphs.

Figure 7. A decrease in mitochondrial membrane potential and ATP deficiency precede the

onset of cell death.

(a) JC-1 staining of hRPTECs treated with puberulic acid and statistical analysis of red/green ratio.

Red color indicates J-aggregate and green color indicates JC-1 monomer. n = 18 in each

condition.

(b) ATP levels were measured and normalized to the respective control group at each time point.

The values at 0 h represent theoretical references. n = 6 for 6h, n=9 for 24h, and n = 3 for 48h.

statistical test: Kruskal–Wallis

References

1   Gabardi, S., Munz, K. & Ulbricht, C. A review of dietary supplement-induced renal
dysfunction. *Clin J Am Soc Nephrol* **2**, 757-765 (2007).
https://doi.org/10.2215/cjn.00500107
2   Knapik, J. J., Trone, D. W., Steelman, R. A., Farina, E. K. & Lieberman, H. R. Adverse
effects associated with use of specific dietary supplements: The US Military Dietary
Supplement Use Study. *Food Chem Toxicol* **161**, 112840 (2022).
https://doi.org/10.1016/j.fct.2022.112840
3   LaW, M. o. H. *Information on Adverse Events associated with Beni-koji*
(Red Yeast Rice) related Products.,
<https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/shokuhin/daietto/index_00005
.html> (2024).
4   Higa, Y. *et al.* Divergence of metabolites in three phylogenetically close Monascus species
(M. pilosus, M. ruber, and M. purpureus) based on secondary metabolite biosynthetic gene
clusters. *BMC Genomics* **21**, 679 (2020). https://doi.org/10.1186/s12864-020-06864-9
5   Fukami, H. *et al.* A Review of Red Yeast Rice, a Traditional Fermented Food in Japan and
East Asia: Its Characteristic Ingredients and Application in the Maintenance and
Improvement of Health in Lipid Metabolism and the Circulatory System. *Molecules* **26**
(2021). https://doi.org/10.3390/molecules26061619
6   Maiguma, M. *et al.* Successful treatment of acute tubulointerstitial nephritis probably due
to Benikoji CholesteHelp(®), a supplement containing red yeast rice. *CEN Case Rep* **14**,
24-28 (2025). https://doi.org/10.1007/s13730-024-00897-9
7   Maruyama, H. *et al.* Successful Resolution of Suspected Red Yeast Rice-induced
Nephropathy. *Intern Med* (2025). https://doi.org/10.2169/internalmedicine.4908-24
8   Miyazaki, R. *et al.* Acute kidney tubular injury after ingestion of red yeast rice supplement.
Clin Kidney J **17**, sfae151 (2024). https://doi.org/10.1093/ckj/sfae151
9   Shinzawa, M. *et al.* A nationwide questionnaire study evaluated kidney injury associated
with Beni-koji tablets in Japan. *Kidney Int* **107**, 530-540 (2025).
https://doi.org/10.1016/j.kint.2024.11.027
10   Tanaka, S. *et al.* Novel compounds isolated from health food products containing beni-koji
(red yeast rice) with adverse event reports. *J Nat Med* **78**, 845-848 (2024).
https://doi.org/10.1007/s11418-024-01827-w

11 Yoshinari, T. *et al.* Mechanism of puberulic acid contamination in red yeast rice tablets
that caused a serious food poisoning outbreak in Japan. *Proc Jpn Acad Ser B Phys Biol Sci*
(2025). https://doi.org/10.2183/pjab.101.017

12 Nakanoh, H. *et al.* Development and Validation of a Stem Cell–Based Kidney Organoid
Platform for Nephrotoxicity Assessment. *medRxiv*, 2025.2004.2030.651410 (2025).
https://doi.org/10.1101/2025.04.30.651410

13 Nakanoh, H. *et al.* in *Am J Nephrol*   1-9 (© 2025 The Author(s). Published by S.
Karger AG, Basel., 2025).

14 Iwatsuki, M. *et al.* In vitro and in vivo antimalarial activity of puberulic acid and its new
analogs, viticolins A-C, produced by Penicillium sp. FKI-4410. *J Antibiot (Tokyo)* **64**, 183-
188 (2011). https://doi.org/10.1038/ja.2010.124

15 Lukinich-Gruia, A. T. *et al.* Aristolochic acid I as an emerging biogenic contaminant
involved in chronic kidney diseases: A comprehensive review on exposure pathways,
environmental health issues and future challenges. *Chemosphere* **297**, 134111 (2022).
https://doi.org/10.1016/j.chemosphere.2022.134111

16 Cui, T. *et al.* Clinical and safety outcomes associated with aristolochic acid exposure: a
systematic review and meta-analysis. *Toxicol Mech Methods*, 1-11 (2025).
https://doi.org/10.1080/15376516.2025.2457340

17 Li, C. *et al.* Unveiling correlations between aristolochic acids and liver cancer:
spatiotemporal heterogeneity phenomenon. *Chin Med* **19**, 132 (2024).
https://doi.org/10.1186/s13020-024-01003-y

18 Ichimura, T. *et al.* Kidney injury molecule-1 is a phosphatidylserine receptor that confers
a phagocytic phenotype on epithelial cells. *The Journal of clinical investigation* **118**, 1657-
1668 (2008). https://doi.org/10.1172/jci34487

19 Mori, Y. *et al.* KIM-1 mediates fatty acid uptake by renal tubular cells to promote
progressive diabetic kidney disease. *Cell Metab* **33**, 1042-1061.e1047 (2021).
https://doi.org/10.1016/j.cmet.2021.04.004

20 Ichimura, T. *et al.* Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion
molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after
injury. *The Journal of biological chemistry* **273**, 4135-4142 (1998).

21 Yang, L., Besschetnova, T. Y., Brooks, C. R., Shah, J. V. & Bonventre, J. V. Epithelial cell
cycle arrest in G2/M mediates kidney fibrosis after injury. *Nat Med* **16**, 535-543, 531p
following 143 (2010). https://doi.org/10.1038/nm.2144

22   Ferenbach, D. A. & Bonventre, J. V. Mechanisms of maladaptive repair after AKI leading
to accelerated kidney ageing and CKD. *Nat Rev Nephrol* **11**, 264-276 (2015).
https://doi.org/10.1038/nrneph.2015.3

23   O'Sullivan, E. D., Hughes, J. & Ferenbach, D. A. Renal Aging: Causes and Consequences.
J Am Soc Nephrol **28**, 407-420 (2017). https://doi.org/10.1681/ASN.2015121308

24   Anders, H. J. & Schaefer, L. Beyond tissue injury-damage-associated molecular patterns,
toll-like receptors, and inflammasomes also drive regeneration and fibrosis. *J Am Soc*
Nephrol **25**, 1387-1400 (2014). https://doi.org/10.1681/ASN.2014010117

25   Zhang, Q. *et al.* Circulating mitochondrial DAMPs cause inflammatory responses to injury.
Nature **464**, 104-107 (2010). https://doi.org/10.1038/nature08780

26   Nicotera, P., Leist, M. & Ferrando-May, E. Intracellular ATP, a switch in the decision
between apoptosis and necrosis. *Toxicol Lett* **102-103**, 139-142 (1998).
https://doi.org/10.1016/s0378-4274(98)00298-7

27   Zubair, M. & Bokhari, S. R. A. in *StatPearls*   (2025).

28   Leist, M., Single, B., Castoldi, A. F., Kuhnle, S. & Nicotera, P. Intracellular adenosine
triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis.
J Exp Med **185**, 1481-1486 (1997). https://doi.org/10.1084/jem.185.8.1481

29   Eguchi, Y., Shimizu, S. & Tsujimoto, Y. Intracellular ATP levels determine cell death fate
by apoptosis or necrosis. *Cancer Res* **57**, 1835-1840 (1997).

30   Tsuchiya, K., Wang, W., Giebisch, G. & Welling, P. A. ATP is a coupling modulator of
parallel Na,K-ATPase-K-channel activity in the renal proximal tubule. *Proc Natl Acad Sci*
U S A **89**, 6418-6422 (1992). https://doi.org/10.1073/pnas.89.14.6418

31   Forst, A. L., Reichold, M., Kleta, R. & Warth, R. Distinct Mitochondrial Pathologies
Caused by Mutations of the Proximal Tubular Enzymes EHHADH and GATM. *Front*
Physiol **12**, 715485 (2021). https://doi.org/10.3389/fphys.2021.715485

a

b

| KIM-1 | α-SMA | merge |

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

a

b

Figure 7